FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Timothy Henkel

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Phenomena

Metabolic Clearance Rate

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
James A Dowell; Martin Stogniew; David Krause; Timothy Henkel; Bharat D Damle
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.
Mary Beth Dorr; Daniela Jabes; Marco Cavaleri; James Dowell; Giorgio Mosconi; Adriano Malabarba; Richard J White; Timothy Henkel
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
Issam Raad; Rabih O Darouiche; Jose A Vazquez; Arnold Lentnek; Ray Hachem; Hend Hanna; Beth Goldstein; Timothy Henkel; Elyse Seltzer
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Timothy Henkel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: James A Dowell; Martin Stogniew; David Krause; Timothy Henkel; Bharat D Damle
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.
Journal of clinical pharmacology 2007;47(3):305-14.
2005: Mary Beth Dorr; Daniela Jabes; Marco Cavaleri; James Dowell; Giorgio Mosconi; Adriano Malabarba; Richard J White; Timothy Henkel
Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
The Journal of antimicrobial chemotherapy 2005;55 Suppl 2():ii25-30.
2005: Issam Raad; Rabih O Darouiche; Jose A Vazquez; Arnold Lentnek; Ray Hachem; Hend Hanna; Beth Goldstein; Timothy Henkel; Elyse Seltzer
Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(3):374-80.
2005: James A Dowell; Martin Stogniew; David Krause; Timothy Henkel; Irving E Weston
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
Journal of clinical pharmacology 2005;45(2):227-33.
2004: David S Krause; A E Simjee; Christo van Rensburg; Johann Viljoen; THOMAS WALSH; Beth P Goldstein; Michele Wible; Timothy Henkel
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(6):770-5.
2004: David S Krause; John Reinhardt; Jose A Vazquez; Annette C Reboli; Beth P Goldstein; Michele Wible; Timothy Henkel
Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia.
Antimicrobial agents and chemotherapy 2004;48(6):2021-4.
2004: James A Dowell; William Knebel; Tom Ludden; Martin Stogniew; David Krause; Timothy Henkel
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
Journal of clinical pharmacology 2004;44(6):590-8.
2003: Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Timothy Henkel
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(10):1298-303.